• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 30, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Bioengineering

Fertility drug appears to stop Ebola virus

Bioengineer by Bioengineer
September 18, 2013
in Bioengineering
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A class of drugs that includes treatments for breast cancer and infertility appears able to inhibit the deadly, incurable Ebola virus, new research suggests.

As part of a collaborative effort, researchers at the University of Virginia School of Medicine have shown that the drugs clomiphene, which is used to treat female infertility, and toremifene, used to treat breast cancer, can effectively block Ebola infections in mice. The drugs, and others with similar structures, appear to prevent the virus from delivering its RNA into the cytoplasm of cells. Without the ability to deliver its genetic payload, the virus degrades quickly and is removed from the body.

“These are among the first FDA-approved compounds shown to be effective against Ebola in mouse models,” U.Va. researcher Judith M. White said. “With a virus this lethal, you want something to combat it.”

Ebola infections carry fatality rates of up to 90 percent. It strikes both humans and other primates, and there are fears it could be used as a biological weapon. There’s no cure, so it’s imperative that scientists find effective treatments. The new discovery eventually could lead to the repurposing of FDA-approved drugs, already available for prescription, to combat the virus.

The findings are the result of an innovative partnership of academia, government and private industry. The drugs’ potential use against Ebola was first identified by investigators at biopharmaceutical company Zalicus and the U.S. Army Medical Research Institute of Infectious Diseases; they then turned to U.Va. for its expertise in figuring out how the drugs worked against the virus. U.Va. has developed an important assay that lets researchers analyze each step of the cellular infection process, allowing them to determine how the two drugs – and potentially other, similar drugs – undercut Ebola.

The U.Va. researchers concluded that the drugs were preventing the virus from fusing with membranes in targeted cells, essentially hemming in the viral RNA.

“Ebola virus is in a race against the clock when it gets into the cell,” said Jason Shoemaker, a postdoctoral fellow who developed the assay as a graduate student in White’s lab. “We want to lock the door on it.”

The research could have important ramifications for understanding the Ebola infection process. “There is a lot about Ebola viruses that is very strange compared to other viruses,” Shoemaker said. “Any work that helps uncover more information about the viral entry pathway is helpful.”

The U.Va. research posed no health risk, as the researchers used what are known as “virus-like particles” that contain no genetic material.

In evaluating the drugs’ potential for stopping Ebola, U.Va. worked closely with both Zalicus and the Army Medical Research Institute, which handled the work involving live viruses.

White noted the unconventional process that led to the discovery of the drugs’ anti-Ebola properties. Instead of attempting to develop a drug starting at the molecular level, Zalicus began by looking for existing drugs that could inhibit Ebola.

“This whole approach is the reverse of how a molecular biologist might approach the problem,” White said. “If we’d gone with the molecular approach, we would never have looked at this class of drugs.”

The findings have been published online by the journal Science Translational Medicine. The U.Va. researchers plan to continue their collaborative efforts and will look for drugs that may be even better at battling Ebola than clomiphene and toremifene.

“Our findings suggest we are not talking about one specific drug,” Shoemaker said. “It’s a whole family. One might be better.”

Share12Tweet8Share2ShareShareShare2

Related Posts

Why is the first Turkish bioengineering promotion website, Biyomuhendislik.com, so important?

February 4, 2023

Robo-fish

September 19, 2016

Mice born from ‘tricked’ eggs

September 17, 2016

UCLA researchers use stem cells to grow 3-D lung-in-a-dish

September 16, 2016
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    87 shares
    Share 35 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    73 shares
    Share 29 Tweet 18
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    59 shares
    Share 24 Tweet 15
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    56 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tunable Microstructures in Bionic Bone Scaffold Design

Hybrid Genetic Algorithm Optimizes Neural Network Image Restoration

Age Impacts Brain’s Spatial Geometry, Study Finds

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.